Medical artificial intelligence (AI) solution development company VUNO gained the Class IIa CE markings for five of their AI solutions.

June 24, 2020 — Medical artificial intelligence (AI) solution development company VUNO gained the Class IIa CE markings for five of their AI solutions.

The five CE marked solutions are: VUNO Med-BoneAge, VUNO Med-DeepBrain, VUNO Med-Chest X-Ray, VUNO Med–Fundus AI and VUNO Med–LungCT AI. These products can now be commercialized and sold in 27 member states of the European Union, the Acceding countries as well as EFTA states. They can also make inroads into countries that recognize the European CE mark such as those in the Middle East, Asia, South and Central America, and Africa.

VUNO was assessed and deemed to meet EU safety and health protection requirements by a Notified Body based on a more stringent clinical validation standards and medical device guidelines. The efficacy and safety of those products demonstrated by a series of clinical research results and papers published in high impact journals and prestigious international seminars were of great help to satisfy the strict requirements.

Of the five MFDS (Ministry of Food and Drug Safety) approved products, four products (VUNO Med-Fundus AI, VUNO Med-Chest X-ray, and VUNO Med - BoneAge and VUNO Med Lung CT AI) received regulatory approval based on the proven effectiveness of performance through clinical trials. With such a robust portfolio, it is anticipated that VUNO Med solutions are to be used as key diagnostic supporting tools across many different medical environments overseas.

Hyun-Jun Kim, CEO of VUNO explained that, "We have been taking proper measures to ensure that VUNO's products obtain classification commensurate with their intended purposes as medical diagnostic supporting tools". He also added that, "In this sense, obtaining CE certification for all five products holds a great significance, and this will be able to accelerate our push for much anticipated global supply of VUNO Med series all around the world."

VUNO has been graining great traction at home and abroad with more than 100 active users of hospitals in Korea alone and is ready to deploy the CE marked products to international business partners and clients across different markets.

For more information: www.vuno.co


Related Content

Feature | Artificial Intelligence

For the past decade, artificial intelligence's (AI) potential in healthcare has been synonymous with speed. In medical ...

Time February 16, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | ARRS

Feb. 11, 2026 —The American Roentgen Ray Society (ARRS) has announced the following radiologists, as well as their ...

Time February 13, 2026
arrow
News | Radiology Business

Feb. 3, 2026 — RadNet, Inc., a provider of high-quality, cost-effective outpatient diagnostic imaging services and ...

Time February 12, 2026
arrow
News | Digital Pathology

Feb. 11, 2026 — Leica Biosystems has announced the global launch of the Leica CM1950 Cryostat with DualEcoTec Cooling ...

Time February 11, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 6, 2026 — A state-of-the-art intraoperative MRI (iMRI) has arrived at the University of Chicago Medicine, one of ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | Computed Tomography (CT)

Feb. 4, 2026 — A new review published in the American Journal of Roentgenology (AJR) finds that advances in CT ...

Time February 04, 2026
arrow
Subscribe Now